Advertisement
Advertisement

APRE

APRE logo

Aprea Therapeutics, Inc. Common stock

0.64
USD
Sponsored
-0.01
-0.92%
Aug 10, 16:00 UTC -4
Closed
exchange

After-Market

0.65

0.00
+0.57%

Aprea Therapeutics, Inc. Common stock Profile

About

Aprea Therapeutics Inc. is a biopharmaceutical company. It is focused on developing and commercializing novel cancer therapeutics which reactivate the mutant tumor suppressor protein, p53. The Company's lead drug candidate, APR-246, a first-in-class small molecule p53 reactivator, is in clinical development for myelodysplastic syndromes, acute myeloid leukemia as well as additional hematologic and solid tumor malignancies. Aprea Therapeutics Inc. is based in Boston, Massachusetts.

Info & Links

CEO

Oren Gilad

Headquarters

3805 Old Easton Road
DOYLESTOWN, PA 18902, UNITED STATES

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

http://www.aprea.com

Auditor

EisnerAmper LLP

Share holders

132

Employees

8

Aprea Therapeutics, Inc. Common stock Statistics

Valuation Measures

Market Capitalization2

8.02M

Enterprise Value

-38.44M

Enterprise Value/EBITDA(ttm)

3.06

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

28.16

Price to Book(mrq)

0.19

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

50.00%

Operating Margin(ttm)

-4405.59%

Profit Margin(ttm)

-19082.57%

Return on Equity(ttm)

-61.03%

Return on Invested Capital(ttm)

-79.02%

Return on Assets(ttm)

-50.24%

Income Statement

Revenue(ttm)

123.20K

Revenue Per Share(ttm)

0.01

Gross Profit(ttm)

123.20K

EBITDA(ttm)3

-12.56M

Net Income Available to Common(ttm)

-11.95M

Diluted EPS(ttm)

-1.54

Share Statistics

Beta (5Y Monthly)

1.52

52-Week Change

-62.10%

S&P 500 52-Week Change

21.65%

S&P 500 Member

No

Stock Optionable

Yes

Total Shares Outstanding1

12.38M

Dividend Yield

0.00%

Float4

11.08M

% Held by Insiders

10.49%

% Held by Institutions

34.19%

Balance Sheet

Total Cash(mrq)

46.47M

Total Cash Per Share(mrq)

3.75

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

8.92%

Quick Ratio(mrq)

8.92%

Book Value Per Share(mrq)

3.47

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.19

Free Cash Flow(ytd)

-2.76M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement